For Patients: An Overview

Sequenom Center for Molecular Medicine^® (Sequenom CMM) is using revolutionary new technology to develop assays that have the potential to advance prenatal care for mothers.

A new noninvasive proprietary technology from Sequenom, called SEQureDx™, enables the detection and analysis of circulating fetal nucleic acid (RNA or DNA) in a pregnant woman. Rather than harvesting placental tissue cells (as is required for chorionic villus sampling), or entering the uterus to sample the amniotic fluid surrounding the baby (as is done with amniocentesis), circulating fetal nucleic acid can be obtained from maternal blood.

By applying our breakthrough technology to diseases and conditions in pregnancy and reproduction, Sequenom CMM believes it can provide physicians advanced tools to assist them in meeting the healthcare needs of their patients.

Follow the links to the left for more information.